
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Supplements and Featured Publications
over 20 years ago
The Role of Gastroprotection in Patients on NSAID Therapyover 20 years ago
Review Questions





